|
 The indication for extended use, if approved, would allow the
antiviral treatment to be given to more patients as coronavirus
infections surge and healthcare systems are pressured by emerging,
highly transmissible variants of the virus.
U.S.-based developer Gilead has submitted data to the European
Medicines Agency (EMA), the watchdog said, adding that its human
medicines committee had started evaluating the latest submissions.
(https://bit.ly/2NA5vrX)
The European Union had conditionally approved remdesivir, the first
COVID-19 therapy on the continent, in July last year for treating
COVID-19 in adults and adolescents over 12 years with pneumonia
requiring oxygen support.
[to top of second column] |
 Any potential endorsements by
the EMA, which have to be formally approved by
the European Commission, would also help Gilead
to broaden sales of a hot-selling treatment that
helped boost its fourth-quarter revenue.
The U.S. drugmaker earlier this month forecast
2021 sales of up to $3 billion for remdesivir,
which is sold under the brand name Veklury.
(Reporting by Pushkala Aripaka in Bengaluru;
Editing by Sriraj Kalluvila and Anil D'Silva)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
